Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).
Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Korea University Hospital, Seoul, Korea, Republic of
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
London Health Sciences Centre, London, Ontario, Canada
Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow, Russian Federation
Eskenazi Health System, Indianapolis, Indiana, United States
Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
WCCT Global, Cypress, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.